Alphamab pre-markets Hong Kong IPO, eyes $1bn valuation

By Jonathan Breen
18 Nov 2019

Alphamab Oncology, a Chinese biopharmaceutical company, kicked off pre-deal investor education for a potential $250m IPO on Monday after gaining approval to list from the Hong Kong Stock Exchange.

Having filed a post-listing hearing prospectus with the HKEX last weekend, Alphamab pre-marketed the IPO this week, according to a source familiar with the matter.

It is targeting a post-IPO market capitalisation of around $1bn with a public float of 25%, added the source. But the final size ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial